TRACON Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, is focused on developing and commercializing therapies for cancer and age-related macular degeneration and fibrotic diseases in the United States. Its lead clinical-stage product includes envafolimab (KN035), an investigational PD-L1 single-domain antibody for the treatment of soft tissue sarcoma. The company’s clinical-stage products also include TRC102, which is a small molecule that is in a phase II clinical trial to treat mesothelioma, a phase I clinical trial to treat solid tumors, and a phase I clinical trial to treat solid tumors and lymphomas. , and phase I trial to treat lung cancer; TRC253, a small molecule, that it is in a phase II clinical trial for the treatment of metastatic castration-resistant prostate cancer; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of the CD73 TJ004309 antibody; Janssen Pharmaceutica NV for the development of TRC253; Case Western Reserve University for the development of TRC102; and cooperative research and development agreement with the National Cancer Institute. The company was previously known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of the CD73 TJ004309 antibody; Janssen Pharmaceutica NV for the development of TRC253; Case Western Reserve University for the development of TRC102; and cooperative research and development agreement with the National Cancer Institute. The company was previously known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of the CD73 TJ004309 antibody; Janssen Pharmaceutica NV for the development of TRC253; Case Western Reserve University for the development of TRC102; and cooperative research and development agreement with the National Cancer Institute. The company was previously known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California. for the development of TRC253; Case Western Reserve University for the development of TRC102; and cooperative research and development agreement with the National Cancer Institute. The company was previously known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California. for the development of TRC253; Case Western Reserve University for the development of TRC102; and cooperative research and development agreement with the National Cancer Institute. The company was previously known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California.
Want to learn how to buy TRACON Pharmaceuticals (TCON) shares Guide
Do you want to buy TRACON Pharmaceuticals (TCON) shares on Nasdaq safely and using a quality and regulated broker? Do you like the fact that you are able to invest your profits every month and get capital gains on the stock market? In this tutorial I am going to show you how you can register an account with DEGIRO , a reliable Dutch investment broker with low commissions, and how you can get your first shares in TRACON Pharmaceuticals, Inc. (TCON) (TCON ) quickly and easily.
The process is simple :
- The first step is that we will register in Degiro, an investment platform where we are going to buy shares of the company TRACON Pharmaceuticals, Inc. (TCON) (TCON).
- Then we will add euros to carry out our 1st investment in the stock market.
- Once we see the funds we will proceed to locate the company TRACON Pharmaceuticals by putting the TICKER in the search engine, in this case it is TCON.
- To finish we are only going to add the number of shares we want to buy, the price at which we buy and the type of order.
Perhaps this checklist has been somewhat concise for you, so I am going to show you step by step with images:
How to register with the DEGIRO broker
First we are going to register in degiro from the following link :
It will ask us for an email, a name and a password to access, and then we will continue from the link that they have sent us by mail.
DEGIRO will continuously ask us for some necessary data in order to accept our identification card . We need to have at hand our passport number, ID or driving license, your mobile or cell phone and the account number that we will place to make our first deposit in IBAN format. If you have no idea which way this format is, you can check this simple tutorial article that we have made .
Once our account is verified, we will have to put money from the Enter / Withdraw tab. We can carry out a transfer that will take between 1-2 days, or make the deposit instantly using Sofort, a 100% secure and 100% reliable payment gateway.
How to buy TRACON Pharmaceuticals (TCON) shares through DeGiro
At the time that we have the money we can invest in our 1st action. You can use the Place Order button that you will find in the right corner or use the DEGIRO search engine and type the ticker. In the following screenshot you will find that I have used the Amazon Ticker but you have to enter (TCON), the TRACON Pharmaceuticals ticker. As we are talking about a stock, we will see that the related businesses and companies are listed and there we will discover to find TRACON Pharmaceuticals. What is key is that the ticker, the name of the action and the market in which it is listed coincide. Amazon is listed on Nasdaq (NDQ) and in your case TRACON Pharmaceuticals, Inc. (TCON) is listed on Nasdaq. This step is very fundamental so make no mistake.
At the time of developing the order we have to pay special attention to what I will explain to you . We may be able to place a limit or market order. Say you want to get a share of TRACON Pharmaceuticals at 6.02, but its current price is much higher. With a limit order we will enter the value at which we calculate to execute the operation and until there are no shares for sale at this value, the purchase of the share will not be made. With a market order you will buy the number of shares that we have added to the currently selling price, which will be very close to the live trading price.
In both cases it is very essential that you look at the type of position: permanent or day . To serve as an example, in Spain, the stock market price is in the morning and until 1:00 p.m., and in the US it corresponds to the afternoon schedule in Spain. If an order is permanent, it will remain until the point where it can be executed, but if you prefer the “of the day” option, at the end of the day, if it has not been carried out, it will be deleted from your Activity – Orders tab. slopes.
I hope this quick text will help you to invest in TRACON Pharmaceuticals. Greetings!
| Company information |
|
company executives
| Name | Title | Payment | exercised | Year of birth |
|---|---|---|---|---|
| Dr. Charles P. Theuer | CEO, President and Director | 905.38k | N/A | 1964 |
| Mr. Scott B. Brown CPA, MS | CFO | 382.82k | N/A | 1981 |
| Mr. Mark C. Wiggins MBA | Bus Chief Officer | 543.99k | N/A | 1956 |
| Mrs Bonne Adams | Executive Vice President of Clinical Operations | N/A | N/A | 1977 |
| Mr Shahe Garabedian | Senior Vice President and Head of Quality Assurance | N/A | N/A | N/A |
| James L. Freddo, MD | Medical director | N/A | N/A | 1955 |
Recent TRACON Pharmaceuticals Events:
Recent Events June 11, 2020 Filed Complete 8-K: Submission of Matters to Vote by Security Holders May 14, 2020 Filed Complete 8-K: Other Events, Financial Statements and Exhibits May 13, 2020 Filed Complete 8- K: Results of Operations and Financial Condition, Financial Statements May 13, 2020 Filed Complete 10-Q: Quarterly Report May 04, 2020 Filed Complete 8-K: Entry into Material Definitive Agreement, Unrecorded Sale of Equ